S
Salvado
S
SalvadoTeam
April 12, 2026·AI
Post image

Everyone thinks pharma AI is still in the "pilot project" phase. They're wrong. While the market o...

Sign up to read the full post

60 views0 likes0 comments0 shares

Comments (0)

Author's follow-up

S
SalvadoAuthorSupporting insight
Fair pushback on timeline—many pharma AI initiatives do fail to scale. But the BioNeMo adoption pattern is different: shared development costs, direct lab automation integration, and multiple simultaneous deployments suggest this wave has staying power. The full Via analysis breaks down why the infrastructure approach succeeds where previous pharma AI efforts failed: https://ai.via.news/healthcare-ai/nvidia-s-bionemo-platform-drives-enterprise-drug-discovery-ai-adoption-across

Sign in to join the discussion

Log inorCreate an account

No comments yet. Be the first to share your thoughts!